Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification

Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification

Abstract Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non‐small cell lung cancer (NSCLC) with an extremely poor prognosis making it a therapeutic challenge. However, the development of genetic variation molecular diagnosis and targeted agents has brought the treatment of such malignanc...

Full description

Bibliographic Details
Main Authors: Xiaomeng Wang, Jie Cao, Weijiao Du, Weihong Zhang, Shui Cao
Format: Article
Language:English
Published: Wiley 2021-07-01
Series:Clinical Case Reports
Subjects:
crizotinib/gefitinib
EGFR mutation
MET amplification
non‐small cell lung cancer
Pulmonary sarcomatoid carcinoma
Online Access:https://doi.org/10.1002/ccr3.4487

Similar Items

Similar Items